Preliminary results of chemo-radiotherapy followed or not by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma. Correlation of the results with WHO categorisation

• Published in: Cancer chemotherapy and pharmacology Vol. 1; no. 4; p. 197
• Main Authors: Misset, J L, Mathé, G, Tubiana, M, Caillou, B, de Vassal, F, Pouillart, P, Gil, M, Tentas, C, Hayat, M, Schwarzenberg, L, Jasmin, C, Delgado, M, Machover, D, Ribaud, P, Musset, M
• Format: Journal Article
• Language: English
• Published: Germany 1978
• Subjects: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Immunotherapy; Lymphoma, Non-Hodgkin - classification; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - radiotherapy; Lymphoma, Non-Hodgkin - therapy; Male; Middle Aged; Neoplasm Staging; Time Factors
• ISSN: 0344-5704
• DOI: 10.1007/BF00257149

We treated 101 patients with advanced (stage III and IV) lymphosarcoma and reticulosarcoma at first presentation of the disease or in relapse according to a protocol combining initial chemotherapy, complementary radiotherapy on icebergs, supplementary chemotherapy, and, finally, active immunotherapy. The overall complete remission rate was about 79% for lymphosarcoma and 73% for reticulosarcoma. About 50% of the patients were still in remission in each of the two diseases at 2 years; 60% of lymphosarcoma and 44% of reticulosarcoma patients achieved 2-year survival. This study shows the prognostic value of the WHO classification for lymphosarcoma and reticulosarcoma: the prognosis of prolymphocytic (centrofollicular) lymphosarcoma is far better than that of the lymphoblastic type, which is in turn better than that of the very poor prognosis of the immunoblastic type. The prognosis of reticulosarcoma is intermediate between that of the best-prognosis and that of the poorest-prognosis type of lymphosarcoma.